JP2024526880A5 - - Google Patents

Info

Publication number
JP2024526880A5
JP2024526880A5 JP2024503534A JP2024503534A JP2024526880A5 JP 2024526880 A5 JP2024526880 A5 JP 2024526880A5 JP 2024503534 A JP2024503534 A JP 2024503534A JP 2024503534 A JP2024503534 A JP 2024503534A JP 2024526880 A5 JP2024526880 A5 JP 2024526880A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical product
antigen
binding fragment
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074007 external-priority patent/WO2023004386A1/en
Publication of JP2024526880A publication Critical patent/JP2024526880A/ja
Publication of JP2024526880A5 publication Critical patent/JP2024526880A5/ja
Pending legal-status Critical Current

Links

JP2024503534A 2021-07-22 2022-07-21 脳標的化組成物及びその使用方法 Pending JP2024526880A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163224848P 2021-07-22 2021-07-22
US63/224,848 2021-07-22
US202163227895P 2021-07-30 2021-07-30
US63/227,895 2021-07-30
PCT/US2022/074007 WO2023004386A1 (en) 2021-07-22 2022-07-21 Brain targeting compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024526880A JP2024526880A (ja) 2024-07-19
JP2024526880A5 true JP2024526880A5 (cg-RX-API-DMAC7.html) 2025-07-29

Family

ID=82899175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503534A Pending JP2024526880A (ja) 2021-07-22 2022-07-21 脳標的化組成物及びその使用方法

Country Status (5)

Country Link
US (1) US20240254210A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373576A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024526880A (cg-RX-API-DMAC7.html)
TW (1) TW202311283A (cg-RX-API-DMAC7.html)
WO (1) WO2023004386A1 (cg-RX-API-DMAC7.html)

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9221900B2 (en) * 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
KR101933197B1 (ko) * 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
NZ723884A (en) 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
TW202239429A (zh) * 2014-02-08 2022-10-16 美商建南德克公司 治療阿茲海默症之方法
EP3405489A1 (en) * 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
DK3570884T3 (da) * 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
MD3672631T3 (ro) * 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici

Similar Documents

Publication Publication Date Title
CN117956995A (zh) 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途
JP5749255B2 (ja) L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
US10206919B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
Green et al. Nicotine enemas for active ulcerative colitis—a pilot study
HERMANS et al. Association of gastric carcinoma with idiopathic late-onset immunoglobulin deficiency
JP2022523530A5 (cg-RX-API-DMAC7.html)
JP2024016209A5 (cg-RX-API-DMAC7.html)
JPH01502909A (ja) 免疫毒素による人間の治療における免疫抑制
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
US5886047A (en) Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
Cortez et al. Acute pulmonary hypersensitivity to furazolidone
JP3837769B2 (ja) 抗ウイルス剤
JP2022526643A5 (cg-RX-API-DMAC7.html)
JP2025521501A5 (cg-RX-API-DMAC7.html)
RU2113805C1 (ru) Пищевая добавка янтавит
Alsaidalani et al. Refractory graves’ disease in an adolescent successfully treated with cholestyramine and subsequent thyroidectomy
RU2220730C2 (ru) Способ лечения герпетического стоматита
Lieber et al. Complications resulting from renal failure in patients with liver disease
JP2023518829A5 (cg-RX-API-DMAC7.html)
JP2006515011A (ja) Hcv併用療法
Woods Susceptibility to experimental pyelonephritis when hormonal hypertension is prevented by hypotensive drugs
RU2024256C1 (ru) Средство для лечения хронических диффузных заболеваний печени
Le Ha et al. Droxidopa for refractory neurogenic orthostatic hypotension in amyloid light chain amyloidosis
RU2174406C2 (ru) СПОСОБ ВВЕДЕНИЯ ПРЕПАРАТА, СОДЕРЖАЩЕГО РЕКОМБИНАНТНЫЙ α2-ИНТЕРФЕРОН
NAKAMA A clinical investigation of clotrimazole (Bay b 5097) cream on skin candidiasis